Have I missed some news again, since it’s already -11% on the board this morning?
The results came out on Friday and were slightly below expectations, but still, the drop is quite steep, especially after sliding for half a year already.
The drop feeds the drop, unfortunately. There’s hardly anything else behind this than more willing sellers than buyers. Q4 was a big disappointment for me and I sold my shares on Friday morning when the price was still at Thursday’s level. I thought Q3’s roughly 10mSEK sales were an alright quarterly sales figure, which would then be grown later, but Q4 saw a 30% setback compared to that, even though Vagivital sold more. In other words, I had overestimated Lunette’s potential significantly (though so far only for one quarter).
Unfortunately, this looks very much like an eternal promise, when despite good products and the right strategy, sales just falter and operations will likely continue to require external financing. There’s enormous potential here, but if the company is bankrupt due to lack of funding, it’s difficult to achieve. I’ll watch from the sidelines for a change, to see if sales pick up a bit. A positive news stream, which I’m still waiting for, could temporarily boost sentiment significantly, but ultimately, much more sales need to be generated.
3 Likes
People on Avanza have been complaining/joking for a long time that a “35 shares” sale moves the stock price 5% in one direction or another 
So there’s no actual news behind that.
1 Like
Lunette has also started selling adult women’s toys on their website. I’m not entirely sure about this direction from a brand perspective, and the competition in this field is quite brutal. I would have preferred to see products like Vagivital sold on the site.
Edit: After reading more, it seems there was also a thought behind this, which was found in the product description:
6 Likes
Well, new bathwater, not really excited about it. Now we need news from the other side of the river. The company’s management could also show their faith and commitment by increasing their ownership in the company:
4 Likes
14.4.2021 klo 18.51
PEPTONIC Medical AB: Erik Sundquist appointed as new CEO in Peptonic Medical AB
The Board of Directors of Peptonic Medical (publ) (Peptonic' or the Company’ today announces that Erik Sundquist is appointed as new CEO after Johan Inborr.
As of today Erik Sundquist will take on the role as CEO of Peptonic Medical AB. Erik has a well documented history of successes in leading roles in the internationally MedTech Industry, amongst other as head of Q-Med in Asia Pacific within women’s health.
Erik has worked as a consultant in Peptonic since 2017 and is now appointed CEO to pace up the company business and sales development globally. He knows the company well.
“We are very happy to welcome Erik Sundquist in the role as CEO in Peptonic Medical to lead commercialization in USA and Asia and to show continuous and rapid growth in our company”, says Hans von Celsing, Chairman of the Board of Peptonic.
Erik Sundquist succeeds Johan Inborr that leaves his employment with Peptonic Medical to instead function as a consultant. Johan Inborr will remain in the company group to support the continuous development of the company. “The competence and experience of Johan Inborr is really important and we are happy that we can continue developing the company together”, says Hans von Celsing.
3 Likes
Net sales of products KSEK 11 381 (1 781)
Gross profit KSEK 6 568 (985), Gross margin 58% (55%)
Operating loss KSEK -6 424 (-5 807)
Loss per share SEK -0.03 (-0.04)
Sales have grown quite well. I wonder if this one will also start moving little by little.
7 Likes
Excerpts from the report:
Preparations for the US launch of VagiVital during the autumn are now in full swing. In parallel, intensive efforts are being made to turn around the sales of Lunette in US, signs of this happening have been observed in the period.
Significant efforts have been put in to streamlining and optimizing synergies between the business units VagiVital and Lunette during the quarter.
Sales of VagiVital during the quarter amounted to KSEK 3 714. The numbers include one shipment to China and a shipment to Orion in Finland. As mentioned above the sales in own digital web shops is growing rapidly at +93% from relatively small numbers. Currently we have own VagiVital on-line shops in Sweden, Norway, Denmark, Germany and UK.
Compared to previous quarter (Q4 2020) the overall Peptonic company group has increased sales with 4 123 KSEK (+57%), at the same time the costs have been reduced with 2 673 KSEK (-17%).
4 Likes
If only the results improved at the same rate. I’ve been following this for a long time, but I think there’s still time to get on board later. There’s certainly a market for the product 
1 Like
So, am I seeing this right? The QtoQ growth is 50%, and Q1 2021 vs Q1 2020, revenue has grown by nearly 650% (Financial Times figure 1.78 MSEK)?
If Q1 2020 only included VagiVital, then sales have doubled over the year, and the company hasn’t even properly gotten started in the US yet. I increased my position by 150% today.
5 Likes
Q1 2020 figures were from before the Lunette acquisition, so that naturally explains a large part of the growth. But yes, for other products as well, sales have indeed been quite brisk.
The stock just doesn’t seem to interest anyone right now, with trading volumes of only tens of thousands of euros on earnings day. But there seems to be potential here if the direction of operations remains the same, I’ll have to add more at some point.
Who knows what happened in 2017 when the share price plunged from SEK 7.3 to SEK 1.1?
Was there a new share issue, bad news.. ?
I couldn’t quickly find an answer on Google or the forum.
On the Indian version of Investing.com (heh - that split info page isn’t found in PMED’s data in other languages), it says that there was a split on May 24, 2017:
https://in.investing.com/equities/peptonic-medical-ab-historical-data-splits
The currencies are probably local, so the divisor is quite hefty:
Here, on the other hand, there’s talk of an issue on May 30, 2017:
1 Like
My interpretation is that this had an impact on the matter, meaning at that point expectations were almost solely dependent on this product, and the drug did not pass that test round. This understandably dampened the mood. Since then, the company’s product portfolio has expanded and new winds are blowing:
"IMPORTANT EVENTS DURING THE PERIOD
- On March 10th, the Company announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of vaginal atrophy, were not met. However, further analyses of the study data showed that the gel, both without and with the active ingredient (oxytocin), had a marked and statistically significant alleviating effect on the Most Bothersome Symptoms (MBS) after the twelve week treatment. To enter a clinical phase 3 programme, a new phase 2b study would be required. Hence, the Company has decided to focus on bringing the oxytocin-free gel to the market as a non-prescription product."
3 Likes
Vagivital to Poland and 236 pharmacies in Sweden 
8 Likes
A new study has been published and the share price has shot up from that huge dip by a bit (+29%). However, there is still work to be done to return to the beginning of the year’s price of SEK 1.7 
7 Likes
It remains to be seen whether they will stick to the schedule planned at the end of last year, according to which the US launch would start in late summer:
While awaiting FDA approval, Peptonic Medical has planned the launch in the American market with the aim of starting sales of VagiVital®️ in late summer 2021. This will be done in close collaboration with doctors to ensure user satisfaction and treatment results. To maximize operations in the American market, the company’s goal is to build the market in collaboration with a local distributor together with the company’s local entrepreneurial organization. Discussions with potential partners are ongoing.
3 Likes
New recommendation and target price of SEK 2.1. The share price then shot up from SEK 1.1.
10 Likes
Doesn’t look good (also holding onto the corona spring lows of 1kr).
3 Likes
406 thousand euros? That’s a big sum for a small company, but they should be able to get through it once sales in the US start now, if their plan still holds.
The plug certainly came out when it hit -20%.
2 Likes